Comparing Mateon Therapeutics (OTCMKTS:MATN) and Rapport Therapeutics (NASDAQ:RAPP)

Rapport Therapeutics (NASDAQ:RAPP) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Institutional & Insider Ownership

0.1% of Mateon Therapeutics shares are held by institutional investors. 39.2% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Rapport Therapeutics and Mateon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Mateon Therapeutics	N/A	-64.66%	-42.92%

Analyst Ratings

This is a summary of current ratings and target prices for Rapport Therapeutics and Mateon Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0	0	3	0	3.00
Mateon Therapeutics	0	0	0	0	0.00

Rapport Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 53.24%. Given Rapport Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Rapport Therapeutics is more favorable than Mateon Therapeutics.

Valuation & Earnings

This table compares Rapport Therapeutics and Mateon Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$34.79 million	N/A	N/A
Mateon Therapeutics	N/A	N/A	-$6.64 million	N/A	N/A

Summary

Rapport Therapeutics beats Mateon Therapeutics on 5 of the 8 factors compared between the two stocks.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.